QLF

Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023

Retrieved on: 
Monday, September 11, 2023
European Respiratory Society, International, Therapy, Week, Serum, RNA-Seq, Safety, FVC, Fibroblast, QLF, ERS, Fibrosis, Vital capacity, Patient, SAN, Congress, IPF, International Congress on Tuberculosis, Idiopathic pulmonary fibrosis, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced presentations made at the European Respiratory Society (ERS) International Congress 2023 taking place from September 9, 2023 to September 13, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced presentations made at the European Respiratory Society (ERS) International Congress 2023 taking place from September 9, 2023 to September 13, 2023.
  • “We are pleased to be sharing non-clinical and clinical data at this important congress, including, for the first time at a scientific session, the final results from our INTEGRIS-IPF Phase 2a trial.
  • Data from this trial support the late-stage development of bexotegrast as part of the BEACON-IPF trial and highlight our commitment to developing potential treatments for fibrotic diseases,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics.
  • Further analysis of circulating integrin β6 in clinical trials may help to better characterize its utility as an early biomarker of response to anti-fibrotic therapy.

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Duchenne muscular dystrophy, Therapy, Senior, TGF, Doctor of Philosophy, Serum, ALP, Pharmacokinetics, FVC, Biomarker, Duchenne, QLF, ELF, Alkaline phosphatase, Fibrosis, Vital capacity, DMD, Novartis, Patient, Investment, SAN, Integrin, IPF, PSC, IND, Tumor microenvironment, Idiopathic pulmonary fibrosis, Primary sclerosing cholangitis, Cirrhosis, Safety, Pharmaceutical industry, Medical imaging, Research

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2023 financial results.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2023 financial results.
  • INTEGRIS-IPF Phase 2a 24-week 320 mg clinical data showed bexotegrast was well tolerated and demonstrated durable improvements in exploratory efficacy endpoints.
  • INTEGRIS-PSC Phase 2a 12-week interim data expected in the third quarter of 2023.
  • Interim 12-week data from approximately 84 patients in the 40, 80 and 160 mg cohorts is expected in the third quarter of 2023.

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

Retrieved on: 
Wednesday, May 24, 2023
COL1A1, Mahru, Therapy, ITGB6, Serum, ATS, VIM, Vanderbilt University Medical Center, FVC, Biomarker, Fibroblast, American Thoracic Society, QLF, White lung, Fibrosis, Vital capacity, International Conference on Afghanistan, London (2010), HIV disease progression rates, SAN, IPF, Death, Gene, Conference, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Vaccine, Medicine

“Data presented at this year’s ATS conference highlight some of the strong foundational work conducted and encouraging interim clinical results from our Phase 2a INTEGRIS-IPF trial that warrant the progression of bexotegrast into late-stage clinical development,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics.

Key Points: 
  • “Data presented at this year’s ATS conference highlight some of the strong foundational work conducted and encouraging interim clinical results from our Phase 2a INTEGRIS-IPF trial that warrant the progression of bexotegrast into late-stage clinical development,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics.
  • In an oral presentation, Lisa H. Lancaster, M.D., Professor of Medicine at Vanderbilt University Medical Center and principal investigator of the INTEGRIS-IPF Phase 2a trial, reviewed 12-week data from the trial.
  • Results from a differential gene expression analysis suggest the mechanism of action of bexotegrast may be both independent of, and complementary to, that of currently approved therapies.
  • Results also demonstrated the utility of combining single cell transcriptomic techniques with fibrotic human tissue to evaluate the mechanism of action of novel anti-fibrotic therapies, such as bexotegrast.

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023
Exercise, Initiation, Therapy, Duchenne muscular dystrophy, TGF, ALP, Pharmacokinetics, FVC, Biomarker, Duchenne, QLF, ELF, Alkaline phosphatase, Fibrosis, Plasma, Vital capacity, DMD, Novartis, Investment, Patient, Integrin, Research, IPF, PSC, IND, Tumor microenvironment, Idiopathic pulmonary fibrosis, Primary sclerosing cholangitis, Cirrhosis, Safety, Security (finance), Pharmaceutical industry, Medical imaging

SOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported first quarter 2023 financial results.

Key Points: 
  • $577 million in cash, cash equivalents and short-term investments at end of first quarter 2023,
    SOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported first quarter 2023 financial results.
  • INTEGRIS-PSC Phase 2a 12-week clinical data expected in the third quarter of 2023.
  • Initiation of a Phase 1 first-in-human trial of PLN-101095 in oncology expected in the second quarter of 2023.
  • Initiation of a Phase 1 trial in patients with solid tumors that are resistant to immune checkpoint inhibitors is expected in the second quarter of 2023.

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Retrieved on: 
Sunday, April 30, 2023
University of Southern California, University, Week, Serum, HRCT, Telephone, Clinical trial, Pharmacokinetics, Vanderbilt University Medical Center, ILD, Keck School of Medicine of USC, VAS, Biomarker, QLF, Cough, MCID, Interest, Plasma, Fibrosis, Visual analogue scale, Conference call, SAE, Vital capacity, Walking, HIV disease progression rates, Patient, Standard of care, SAN, Webcast, Mortality, IPF, Therapy, Death, III, Conference, Idiopathic pulmonary fibrosis, Caregiver, Safety, Pharmaceutical industry, Medical imaging, Medicine, FVC

The 320 mg dose group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated up to 40 weeks and displayed a favorable pharmacokinetic profile.

Key Points: 
  • The 320 mg dose group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated up to 40 weeks and displayed a favorable pharmacokinetic profile.
  • The 320 mg group enrolled 21 patients in the active arm and 8 patients in the placebo arm.
  • The primary endpoint of the INTEGRIS-IPF trial was the evaluation of the safety and tolerability of bexotegrast.
  • Bexotegrast was well tolerated at 320 mg up to 40 weeks of treatment with no drug-related serious adverse events (SAE) reported.

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results

Retrieved on: 
Thursday, March 9, 2023
Pharmacokinetics, Idiopathic pulmonary fibrosis, IND, ELF, Novartis, Primary sclerosing cholangitis, Cirrhosis, Therapy, QLF, SAN, HIV disease progression rates, FDA, Fibrosis, Patient, Investigational New Drug, Serum, Public expenditure, Research, Mortality, Orphan drug, PSC, FVC, NASH, Exercise, Investment, Alkaline phosphatase, Safety, Human resources, Plasma, Integrin, ALP, Ironwood Pharmaceuticals, Biomarker, IPF, Pharmaceutical industry, Life insurance, EU

SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported fourth quarter 2022 financial results.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported fourth quarter 2022 financial results.
  • We are positioned to deliver multiple clinical catalysts in 2023," said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant Therapeutics.
  • Exploratory efficacy endpoints demonstrated strong treatment effects on FVC, Quantitative Lung Fibrosis (QLF) imaging and biomarkers over 12 weeks.
  • INTEGRIS-IPF Phase 2a trial on track for final 24-week data readout from the bexotegrast 320 mg dose group in the second quarter of 2023.

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis

Retrieved on: 
Sunday, January 22, 2023
Standard of care, QLF, Safety, Biomarker, Pharmacokinetics, Webcast, III, Șaeș, Idiopathic pulmonary fibrosis, Patient, FVC, SAN, HRCT, FEV1/FVC ratio, IPF, Mortality, Serum, Plasma, Therapy, Vital capacity, Pharmaceutical industry, Medical imaging

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with idiopathic pulmonary fibrosis (IPF). The 320 mg group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period and displayed a favorable pharmacokinetic profile. The trial’s exploratory efficacy endpoints assessed changes in forced vital capacity (FVC), Quantitative Lung Fibrosis (QLF) imaging and biomarkers. Bexotegrast at 320 mg demonstrated a statistically significant mean increase in FVC from baseline at all timepoints, surpassing all lower dose cohorts, and showed a strong treatment effect on FVC percent predicted (FVCpp), QLF and profibrotic biomarkers versus placebo at 12 weeks.

Key Points: 
  • The INTEGRIS-IPF Phase 2a trial is evaluating bexotegrast at once-daily doses of 40 mg, 80 mg, 160 mg, 320 mg or placebo for 12 weeks in 119 patients with IPF.
  • The 320 mg group enrolled 21 patients in the active arm and 8 patients in the placebo arm.
  • The 320 mg group will continue until all patients have been treated for at least 24 weeks, with final data expected in the second quarter of 2023.
  • Bexotegrast was well tolerated at 320 mg over 12 weeks of treatment with no drug-related severe or serious adverse events (SAEs) reported.

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 8, 2022
IND, PSC, INN, Serum, Agilent Technologies, Partnership, Therapy, Exercise, International, Integrin, Company, Vital capacity, Review, Primary sclerosing cholangitis, Food, SEC, News, Data monitoring committee, Pharmacokinetics, Research, Patient, Analysis, Result, European Medicines Agency, COVID-19, Private Securities Litigation Reform Act, Fibrosis, Investigational New Drug, Risk, Conversation, Nasdaq, FVC, QLF, Regulation of tobacco by the U.S. Food and Drug Administration, Public expenditure, Clinical trial, Muscular dystrophy, Fatty liver disease, FDA, SAN, GLOBE, YouTube, Idiopathic pulmonary fibrosis, Oxford, Investment, NASH, Orphan, Financial condition report, Șaeș, Annual report, Safety, Biomarker, DSMB, Cirrhosis, IPF, Pharmaceutical industry, Novartis, Inc.

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported third quarter 2022 financial results.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported third quarter 2022 financial results.
  • A treatment effect was observed at all three doses tested on top of standard of care therapy and as monotherapy.
  • INTEGRIS-IPF Phase 2a trial of PLN-74809 (bexotegrast) at 320 mg on track for 12-week data readout in early first quarter 2023.
  • Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Retrieved on: 
Thursday, September 1, 2022
European Medicines Agency, GLP, Novartis, COVID-19, HRCT, Safety, Pharmacokinetics, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, SAN, YouTube, FVC, PSC, Data monitoring committee, Risk, Result, Food, Orphan, Conversation, LinkedIn, SEC, Muscular dystrophy, Fibrosis, DSMB, Integrin, GLOBE, Â, Vital capacity, Nasdaq, FDA, Cirrhosis, News, NASH, Twitter, Biomarker, IPF, Facebook, Toxicology, Financial condition report, Primary sclerosing cholangitis, QLF, Annual report, Fatty liver disease, Analysis, Private Securities Litigation Reform Act, Idiopathic pulmonary fibrosis, Patient, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced a positive safety review of the ongoing INTEGRIS-IPF Phase 2a trial of PLN-74809 at 320 mg once-daily dose in patients with idiopathic pulmonary fibrosis (IPF) from a regularly scheduled meeting of its independent Data Safety Monitoring Board (DSMB). The DSMB recommended the INTEGRIS-IPF trial continue without modification.

Key Points: 
  • Interim 12-week data from the 320 mg dose cohort from this Phase 2a, randomized, double-blind, placebo-controlled trial are expected in early 2023.
  • This positive safety review marks an important milestone in the development of PLN-74809.
  • Given 320 mg is the highest dose planned to be tested in the PLN-74809 program, the positive DSMB review significantly builds on the favorable safety profile seen to date, said ric Lefebvre, M.D., Chief Medical Offer at Pliant.
  • In July, Pliant announced positive topline data from the INTEGRIS-IPF trial of 40 mg, 80 mg and 160 mg 12-week dose cohorts.

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022
GLOBE, SEC, Investment, Facebook, Integrin, Research, Annual report, Plasma protein binding, Patient, Muscular dystrophy, Fast track (FDA), Fatty liver disease, PSC, FVC, News, Idiopathic pulmonary fibrosis, QLF, Food, NDA, Vital capacity, Private Securities Litigation Reform Act, Analysis, Fibrosis, SAN, Partnership, Safety, Orphan, Primary sclerosing cholangitis, Nasdaq, Pharmacokinetics, Investigational New Drug, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND World's Fair Line, Mortality, IPF, European Medicines Agency, NASH, Therapy, COVID-19, Cirrhosis, Program, Financial condition report, ELF, Fast Track, Result, FDA, Biomarker, ALP, YouTube, IND, Achievement, Conversation, Review, Company, Twitter, Risk, LinkedIn, Pharmaceutical industry, Medical imaging, Novartis

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2022 financial results.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2022 financial results.
  • A highlight to our teams progress in 2022 is the positive safety and efficacy data from the INTEGRIS-IPF Phase 2a trial.
  • Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.
  • For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook and YouTube.